Wyeth got the EU's approval to sell a new-and-improved version of its BeneFix hemophilia B treatment. The new version comes in a more concentrated form for faster infusion, and it's available in a larger-dosage vial. Wyeth recently took over marketing of the drug, developed by Genetics Institute, from Baxter. Genetics Institute has been a Wyeth subsidiary since 1996. Release